Patents by Inventor Timothy J. Barberich

Timothy J. Barberich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • R-hydroxynefazodone
    Patent number: 6465470
    Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.
    Type: Grant
    Filed: November 19, 2001
    Date of Patent: October 15, 2002
    Assignee: Sepracor Inc.
    Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle
  • S-hydroxynefazodone
    Patent number: 6465469
    Abstract: The S-isomer of the hydroxy metabolite of nefazodone, S-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. S-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: October 15, 2002
    Assignee: Sepracor Inc.
    Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle
  • Methods for treating apnea and apnea disorders using optically pure (+) norcisapride
    Publication number: 20020147220
    Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) stereoisomer.
    Type: Application
    Filed: February 15, 2002
    Publication date: October 10, 2002
    Applicant: Sepracor Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
    Publication number: 20020086880
    Abstract: The invention relates to methods and compositions for the prevention, treatment, or management of gastrointestinal disorders or symptoms thereof, employing two or more agents or compounds to provide a triple site action on 5-HT3 receptors, 5-HT4 receptors, and at least one of H2 receptors and proton pumps.
    Type: Application
    Filed: January 10, 2002
    Publication date: July 4, 2002
    Applicant: SEPRACOR, INC.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
    Publication number: 20020086881
    Abstract: The invention relates to methods and compositions for the prevention, treatment, or management of gastrointestinal disorders or symptoms thereof, employing two or more agents or compounds to provide a triple site action on 5-HT3 receptors, 5-HT4 receptors, and at least one of H2 receptors and proton pumps.
    Type: Application
    Filed: January 10, 2002
    Publication date: July 4, 2002
    Applicant: SEPRACOR, INC.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • R-hydroxynefazodone
    Patent number: 6384037
    Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.
    Type: Grant
    Filed: April 7, 2000
    Date of Patent: May 7, 2002
    Assignee: Sepracor Inc.
    Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle
  • Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
    Publication number: 20020051815
    Abstract: Methods for the treatment, management, or prevention of apnea and apnea disorders, or symptoms thereof, using a therapeutically effective amount of substantially optically pure R(+) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(−) stereoisomer.
    Type: Application
    Filed: November 1, 2001
    Publication date: May 2, 2002
    Applicant: Sepracor Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • R-hydroxynefazodone
    Publication number: 20020052382
    Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.
    Type: Application
    Filed: November 19, 2001
    Publication date: May 2, 2002
    Applicant: Sepracor Inc.
    Inventors: Timothy J. Barberich, Paul D. Rubin, William E. Yelle
  • R-lansoprazole compositions and methods
    Publication number: 20020042433
    Abstract: Methods and compositions are disclosed utilizing optically pure (+) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (+) isomer is also useful for the treatment of gastroesophageal reflux. (+) Lansoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Application
    Filed: October 17, 2001
    Publication date: April 11, 2002
    Applicant: SEPRACOR INC.
    Inventors: William E. Yelle, Timothy J. Barberich, Paul D. Rubin
  • Methods for treating irritable bowel syndrome using optically pure (+) norcisapride
    Patent number: 6369079
    Abstract: Methods for the prevention, treatment, or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythnia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (−) stereoisomer.
    Type: Grant
    Filed: February 29, 2000
    Date of Patent: April 9, 2002
    Assignee: Sepracor, Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Methods and compositions using (?) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
    Patent number: 6362202
    Abstract: The invention relates to methods and compositions for the prevention, treatment, or management of gastrointestinal disorders or symptoms thereof, employing two or more agents or compounds to provide a triple site action on 5-HT3 receptors, 5-HT4 receptors, and at least one of H2 receptors and proton pumps.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: March 26, 2002
    Assignee: Sepracor Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
    Patent number: 6353005
    Abstract: The invention relates to methods and compositions for the prevention, treatment, or management of gastrointestinal disorders or symptoms thereof, employing two or more agents or compounds to provide a triple site action on 5-HT3 receptors, 5-HT4 receptors, and at least one of H2 receptors and proton pumps.
    Type: Grant
    Filed: February 22, 2000
    Date of Patent: March 5, 2002
    Assignee: Sepracor, Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • S-lansoprazole compositions and methods
    Publication number: 20010025107
    Abstract: Methods and compositions are disclosed utilizing optically pure (−) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Lansoprazole is an inhibitor of H+ release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.
    Type: Application
    Filed: May 11, 2001
    Publication date: September 27, 2001
    Inventors: Timothy J. Barberich, William E. Yelle, Paul D. Rubin
  • Method for treating asthma utilizing optically pure ( R ) - salmeterol
    Publication number: 20010018458
    Abstract: The optically pure R(−) isomer of salmeterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(−) isomer of salmeterol for treating asthma while minimizing toxicity and other side effects associated with salmeterol.
    Type: Application
    Filed: April 10, 2001
    Publication date: August 30, 2001
    Inventors: Timothy J. Barberich, James W. Young
  • Method for treating bronchospasm using optically pure R(-) albuterol
    Patent number: 6083993
    Abstract: The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: July 4, 2000
    Assignee: Sepracor Inc.
    Inventors: Timothy J. Barberich, James W. Young
  • Methods for treating apnea, apnea disorders, bulimia, and other disorders using optically pure (+) norcisapride
    Patent number: 6048879
    Abstract: Methods for the prevention, treatment or management of apnea, apnea disorders, bulimia nervosa, irritable bowel syndrome, urinary incontinence, bradycardia, bradyarrhythmia, syncope, other disorders, or symptoms thereof using (+) norcisapride, or a pharmaceutically acceptable salt thereof, substantially free of its (-) stereoisomer.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: April 11, 2000
    Assignee: Sepracor Inc.
    Inventors: Paul D. Rubin, Timothy J. Barberich
  • Method for treating asthma using optically pure R(-) salmeterol
    Patent number: 5919827
    Abstract: The optically pure R(-) isomer of salmeterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of salmeterol for treating asthma while minimizing toxicity and other side effects associated with salmeterol.
    Type: Grant
    Filed: December 17, 1997
    Date of Patent: July 6, 1999
    Assignee: Sepracor Inc.
    Inventors: Timothy J. Barberich, James W. Young
  • Method for inducing bronchodilation using optically pure R(-) albuterol
    Patent number: 5844002
    Abstract: The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.
    Type: Grant
    Filed: April 21, 1998
    Date of Patent: December 1, 1998
    Assignee: Sepracor, Inc.
    Inventors: Timothy J. Barberich, James W. Young
  • Method for treating asthma using optically pure R(-) albuterol
    Patent number: 5760090
    Abstract: The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.
    Type: Grant
    Filed: August 15, 1996
    Date of Patent: June 2, 1998
    Assignee: Sepracor, Inc.
    Inventors: Timothy J. Barberich, James W. Young
  • Methods of use and compositions of R(-) fluoxetine
    Patent number: 5708035
    Abstract: A method and composition are disclosed utilizing the pure R(-) isomer of fluoxetine which is a potent antidepressant and appetite suppressant substantially free of adverse effects. In addition, a method and composition are disclosed utilizing the pure R(-) isomer of fluoxetine which is useful to treat migraine headaches, pain, in particular chronic pain, psychoactive substance abuse disorders and obsessive compulsive disorders.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: January 13, 1998
    Assignees: Sepracor Inc., McLean Hospital
    Inventors: James W. Young, Timothy J. Barberich, Martin H. Teicher